Current management of funguria

Area of Science:

• Infectious Diseases
• Mycology
• Urology

Background:

• Funguria, or candiduria, is a frequent nosocomial infection, often developing within two weeks of hospitalization.
• Key risk factors include antibacterial therapy, urinary catheterization, urologic procedures, female sex, diabetes, and immunosuppression.
• Candida albicans is the predominant pathogen, and spontaneous resolution is uncommon.

Purpose of the Study:

• To review current findings on the epidemiology and treatment of funguria.
• To compare the efficacy and characteristics of intravesical amphotericin B and oral fluconazole for funguria treatment.
• To identify areas for future research in funguria management.

Main Methods:

• Review of recent findings on funguria epidemiology and treatment.
• Comparison of intravesical amphotericin B and oral fluconazole therapies.
• Analysis of treatment speed, duration of effect, convenience, and cost.

Main Results:

• Both intravesical amphotericin B and oral fluconazole are effective in clearing funguria.
• Intravesical amphotericin B demonstrates faster action, while oral fluconazole provides a more sustained effect.
• Oral fluconazole is more convenient and cost-effective than bladder irrigation.

Conclusions:

• Oral fluconazole presents a delayed but more persistent effect compared to amphotericin B bladder irrigation.
• Further research is needed to clarify the role of intravesical amphotericin B and optimize fluconazole treatment strategies.
• Non-pharmacologic measures are often insufficient without adjunctive pharmacologic therapy.